Johnson & Johnson raises guidance after Q2 sales top $25.3B

Johnson & Johnson reported second-quarter revenue of $25.31 billion, beating the $25.02 billion analyst consensus, as growth in oncology drugs and medical devices offset continued biosimilar pressure on Stelara.

"The results demonstrate the power of our innovation, the depth of our portfolio and the momentum in our pipeline," Joaquin Duato, chairman and chief executive officer at Johnson & Johnson, said.

Adjusted earnings per share came in at $2.90, topping the $2.86 consensus and rising from $2.77 a year earlier. The Innovative Medicine segment posted operational sales growth of 6.8%, led by Darzalex, Carvykti and Tecvayli in oncology and Tremfya in immunology. MedTech grew 3.6% operationally, driven by wound closure, biosurgery and electrophysiology products. US sales rose 7.3% to $14.53 billion, while international sales increased 5.7% to $10.78 billion.

The company raised its full-year 2026 adjusted EPS guidance to a range of $11.60 to $11.75, with a midpoint of $11.68 that sits above the $11.58 analyst consensus. Revenue guidance of $100.8 billion to $101.4 billion came in slightly above the $101.06 billion estimate. Shares fell about 1% in premarket trading Wednesday despite the beat, as investors weighed the outlook against the stock's 25% year-to-date gain.

The guidance raise signals management expects continued momentum from oncology and immunology franchises to sustain growth through year-end. Investors will watch the next quarterly report for updates on the planned DePuy Synthes orthopaedics separation and pipeline progress on Icoyde and the Tecvayli-Darzalex Faspro combination.

This article is for informational purposes only and does not constitute investment advice.